Development of a Recombinant Subunit Vaccine for CCHF

CCHF 重组亚单位疫苗的开发

基本信息

  • 批准号:
    8499241
  • 负责人:
  • 金额:
    $ 26.89万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-06-28 至 2014-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Emerging and reemerging infectious diseases continue to pose serious health threats world-wide. Consequently, the development of measures to mitigate the natural, as well as potential bioterrorist threats of these infectious diseases is an important endeavor. The NIAID Strategic Plan for Biodefense Research is specifically directed at promoting research that can provide solutions to mitigate the threat posed by Category A, B, and C priority pathogens. The development of vaccines against these pathogens provides a strategy to mitigate the potential threat. Crimean-Congo hemorrhagic fever virus (CCHFV) is a significant human pathogen due to it ability cause severe disease and its high fatality rate. CCHFV is classified as a category C priority pathogen due the concern that it could be used as a biological agent. There is currently no effective vaccine or therapy that is widely available to mitigate such a threat. New technologies and production methods may offer the most effective responses to such disease threats. The proposed research aims to develop a vaccine to protect against disease caused by infection with CCHFV using a stable insect cell line expression platform that has previously been used to produce vaccine candidates for other priority pathogens. The platform is based on the production of recombinant subunit proteins that maintain structural and immunogenic integrity. Candidate vaccines against dengue and West Nile virus have already been produced in this system and both have entered clinical trials. Thus, this platform can be scaled for cGMP production and meet FDA regulatory requirements. The expression of the CCHFV Gn and Gc envelope glycoprotein will be evaluated. The complex nature of viral envelope glycoproteins presents challenges in designing and expressing recombinant subunits that maintain native-like structure. The platform proposed for use in this project has the demonstrated capability of producing complex viral envelope proteins with native-like conformation. Successfully expressed recombinant products will be evaluated for immunogenic potential using two novel adjuvant formulations that have dose sparing potential. Based on immunogenicity studies, selected combinations of recombinant proteins and adjuvant will be evaluated in protective efficacy studies utilizing a recently developed mouse challenge model for CCHFV. In addition to vaccine development, the protein subunits produced can be used for development of diagnostic reagents, as well as targets for antiviral drug development. The successful development of a CCHFV vaccine utilizing this stable insect cell platform will not only meet the need for a safe and effective vaccine against CCHFV, it will also help to demonstrate the utility of the platform and pave the way for the development of additional vaccines against NIAID viral priority pathogens.
描述(由申请人提供):新出现和重新出现的传染病继续对全世界的健康构成严重威胁。因此,制定措施减轻这些传染病的自然威胁和潜在的生物恐怖威胁是一项重要的努力。 NIAID 生物防御研究战略计划专门致力于促进能够提供解决方案以减轻 A、B 和 C 类优先病原体所构成威胁的研究。针对这些病原体的疫苗的开发提供了减轻潜在威胁的策略。克里米亚-刚果出血热病毒(CCHFV)是一种重要的人类病原体,因为它能够引起严重的疾病和高致死率。由于担心 CCHFV 可用作生物制剂,CCHFV 被列为 C 类优先病原体。目前还没有广泛可用的有效疫苗或疗法来减轻这种威胁。新技术和生产方法可能对此类疾病威胁提供最有效的应对措施。拟议的研究旨在使用稳定的昆虫细胞系表达平台开发一种疫苗,以预防由 CCHFV 感染引起的疾病,该平台先前已用于生产其他优先病原体的候选疫苗。该平台基于维持结构和免疫原性完整性的重组亚基蛋白的生产。针对登革热和西尼罗河病毒的候选疫苗已经在该系统中生产出来,并且均已进入临床试验。因此,该平台可以扩展用于 cGMP 生产并满足 FDA 监管要求。将评估 CCHFV Gn 和 Gc 包膜糖蛋白的表达。病毒包膜糖蛋白的复杂性质给设计和表达保持天然样结构的重组亚基带来了挑战。提议在该项目中使用的平台已被证明能够生产具有类似天然构象的复杂病毒包膜蛋白。将使用两种具有剂量节约潜力的新型佐剂制剂来评估成功表达的重组产物的免疫原性潜力。基于免疫原性研究,将利用最近开发的 CCHFV 小鼠攻击模型在保护功效研究中评估重组蛋白和佐剂的选定组合。除了疫苗开发之外,产生的蛋白质亚基还可用于开发诊断试剂以及抗病毒药物开发的靶标。利用该稳定昆虫细胞平台成功开发CCHFV疫苗不仅将满足对安全有效的CCHFV疫苗的需求,还将有助于证明该平台的实用性,并为开发针对NIAID病毒优先病原体的其他疫苗铺平道路。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID E CLEMENTS其他文献

DAVID E CLEMENTS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID E CLEMENTS', 18)}}的其他基金

Development of a Cross-Protective New World Encephalitic Alphavirus Subunit Vaccine
交叉保护性新世界脑炎甲病毒亚单位疫苗的研制
  • 批准号:
    10696914
  • 财政年份:
    2023
  • 资助金额:
    $ 26.89万
  • 项目类别:
Chikungunya Recombinant Subunit Vaccine
基孔肯雅热重组亚单位疫苗
  • 批准号:
    9142241
  • 财政年份:
    2016
  • 资助金额:
    $ 26.89万
  • 项目类别:
Chikungunya Recombinant Subunit Vaccine
基孔肯雅热重组亚单位疫苗
  • 批准号:
    9321278
  • 财政年份:
    2016
  • 资助金额:
    $ 26.89万
  • 项目类别:
Cross-Protective Multivalent Vaccine for Tick-Borne Flaviviruses
蜱传黄病毒交叉保护性多价疫苗
  • 批准号:
    10225429
  • 财政年份:
    2015
  • 资助金额:
    $ 26.89万
  • 项目类别:
Development of a Recombinant Subunit Vaccine for CCHF
CCHF 重组亚单位疫苗的开发
  • 批准号:
    8252247
  • 财政年份:
    2012
  • 资助金额:
    $ 26.89万
  • 项目类别:
Recombinant Subunit Vaccine For Tick-Borne Encephalitis
蜱传脑炎重组亚单位疫苗
  • 批准号:
    8143373
  • 财政年份:
    2004
  • 资助金额:
    $ 26.89万
  • 项目类别:
Evaluation of Immunogenicity : Malaria Subunit Vaccine
免疫原性评价:疟疾亚单位疫苗
  • 批准号:
    6443267
  • 财政年份:
    2002
  • 资助金额:
    $ 26.89万
  • 项目类别:
EXPRESSION OF P FALCIPARUM LSA-1 SUBUNITS
恶性疟原虫 LSA-1 亚基的表达
  • 批准号:
    6293636
  • 财政年份:
    2001
  • 资助金额:
    $ 26.89万
  • 项目类别:
EXPRESSION OF MALARIA MSP-1 P42 C-TERMINAL FRAGMENT
疟疾 MSP-1 P42 C 末端片段的表达
  • 批准号:
    2646424
  • 财政年份:
    1998
  • 资助金额:
    $ 26.89万
  • 项目类别:
Development of a MSP1-p42 Subunit Vaccine for Malaria
疟疾 MSP1-p42 亚单位疫苗的开发
  • 批准号:
    6338185
  • 财政年份:
    1998
  • 资助金额:
    $ 26.89万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 26.89万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 26.89万
  • 项目类别:
    Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 26.89万
  • 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 26.89万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 26.89万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 26.89万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 26.89万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 26.89万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 26.89万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 26.89万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了